A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

NCT ID: NCT05687071

Last Updated: 2025-04-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 130 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-27
• Study Completion Date: 2024-11-02

Brief Summary

A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg administered for 52 weeks in patients with hyper-LDL cholesterolemia

Conditions

Hyper-low-density Lipoprotein (LDL) Cholesterolemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ETC-1002 180mg

Group Type: EXPERIMENTAL

180mg of ETC-1002(bempedoic acid)

Intervention Type: DRUG

180mg, tablet, once daily, for 52 weeks

Interventions

180mg of ETC-1002(bempedoic acid)

180mg, tablet, once daily, for 52 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with inadequate response to statins or who have difficulty in treatment with statins as defined below [Inadequate response to statins] Patients with hyper-LDL cholesterolemia who are currently taking or have previously taken statins[and other lipid-modifying therapies(LMTs) if needed] and cannot achieve the lipid management goals of LDL-C [Difficulty in treatment with statins] Patients with hyper-LDL cholesterolemia for whom safety problems have occurred while taking at least one type of statin, and who experienced resolution of the problems after discontinuation or dose reduction, or of those patients who have a history of statin administration and who are judged to have concerns of safety problems associated with the administration or dose increase of statins and who cannot achieve the lipid management goals of LDL-C. Patients must be on the lowest or under the dosage of the approved dose of statin and/or on stable LMT(s).
• Patients with fasting TG levels of <400 mg/dL at screening

Exclusion Criteria

• Females who are pregnant or breast-feeding or who have a positive pregnancy test (urine) result at screening or baseline visits
• Patients with homozygous familial hypercholesterolemia (HoFH)
• Patients who currently have or who have had within the past 3 months prior to screening any cardiovascular diseases, or those who have developed any cardiovascular diseases during the screening
• Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
• Patients with uncontrolled and serious hematologic or coagulation disorders or with hemoglobin of <10.0 g/dL at screening
• Patients with uncontrolled diabetes with HbA1c of ≥9% at screening
• Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × ULN at screening
• Patients with liver disease or dysfunction, including:

• Positive serology for hepatitis B surface antigen (HBsAg) or a positive hepatitis C virus (HCV) antibody test at screening
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or total bilirubin of ≥2 × ULN at screening
• Patients with creatine kinase (CK) of >3 × ULN at screening
• Patients with a history or current renal dysfunction, nephritic syndrome, or nephritis, and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2 at screening

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Takehisa Matsumaru

Role: STUDY_DIRECTOR

Otsuka Pharmaceutical Co., Ltd.

Locations

Rinku General Medical Center

Izumisano, , Japan

Countries

Japan

Other Identifiers

346-102-00003

Identifier Type: -

Identifier Source: org_study_id